Dutch-based Microsure raises €38M to boost robot-assisted microsurgery: Know more

The Netherlands-based Microsure, a company helping microsurgeons excel in robot-assisted microsurgery, announced that it has closed its Series B2 round and raised €38M in development capital.

The Dutch company says it will use the funds to develop its latest microsurgical robot, MUSA-3, for clinical trials, followed by filing for FDA approval in the US and CE marking in Europe.

Investors supporting Microsure

Amsterdam-based Invest-NL contributed €5M in this round, including the conversion of a previous loan. Invest-NL is a private company financed with public funds. Its aim is to make the Netherlands more sustainable and innovative.

Several new private and public investors also participated in this round, including the European Innovation Council Fund (EICF), the Swiss Kineo and other prominent private investor groups.

Existing investors, including Innovation Industries, BOM Ventures, private investors Ten Cate Investerings Maatschappij (TCIM), Venturing Tech, Eindhoven University of Technology (TU/e) and the founders of Microsure, also supported Microsure in this round.

Robot-assisted microsurgery

Founded in 2016, Microsure’s microsurgical robot technology enhances precision, stability, and control in microsurgery, enabling surgeons to perform complex operations with unprecedented accuracy.

Microsure offers high-precision microsurgical robots like the MUSA-2 and the upcoming MUSA-3. These robots enable supermicrosurgeons to operate with sub-millimetre precision, allowing them to work comfortably and efficiently on even smaller anatomical structures. 

MUSA-2, the first CE-certified microsurgical robot, has been used in clinical studies and received feedback from professionals, which has influenced the development of MUSA-3. 

Its key features include scaled movements, tremor filtration, and the ability to use the surgeon’s own instruments, enhancing precision and control.

By minimising human hand movements and filtering natural tremors, the system allows surgeons to suture even tiny, invisible blood vessels. This advancement reduces complications, improves patient outcomes, and makes complex microsurgery accessible to a wider range of surgeons. 

According to Microsure, its technology has the potential to reduce healthcare costs while enhancing patient safety and treatment effectiveness.

The company’s collaborative approach with supermicrosurgeons ensures continuous improvement and its vision is to leave no patient in need of microsurgery untreated.

Surgeon console

MUSA-3 is designed to enhance precision and stability during suturing procedures. Its dexterity and stability enable surgeons to navigate various wound plane orientations with ease, even in challenging vertically oriented wounds. 

Unlike traditional methods, the company says that MUSA-3 eliminates the need for external surfaces for hand stability, allowing surgeons to perform complex manoeuvres seamlessly. This innovation marks a significant step forward in the world of microsurgery, promising more efficient and effective surgical interventions.

With the MUSA-3 system, surgeons can comfortably operate from a console, utilising digital or hybrid microscopes for precision. This setup promotes an ergonomic position, crucial for prolonged surgeries. 

Surgeons control MUSA-3 through joysticks with a broad range of movement, ensuring freedom and precision. 

The system transfers these joystick movements to robotic arms, enhancing accuracy through movement scaling and tremor filtering. This integrated approach facilitates precise microsurgery as well as prioritises the surgeon’s comfort and control during procedures.

Currently, MUSA-3 is an investigational device and not yet for sale, pending the various local regulatory clearances and release processes.